Absci Corporation · NASDAQ:ABSI

Absci — 2026 J.P. Morgan Healthcare Conference

23 slides from Absci's conference presentation, January 2026

Slide 1: Generative AI Drug Creation
GENERATIVE AI DRUG CREATION 2026 J.P. MORGAN HEALTHCARE CONFERENCE
Slide 2: Disclaimers
GENERATIVE AI DRUG CREATION Disclaimers 1 2 FORWARD-LOOKING STATEMENTS MARKET AND STATISTICAL Statements contained in this press release regarding matters that are not INFORMATION historical facts are “forward-looking statements” within the meaning of the This presentation also contains estimates an
Slide 3: From Code to Clinic: Industrializing Drug Discovery
FROM CODE TO CLINIC Industrializing Drug Discovery $10-15mil (Absci) DATA TO 1 INVESTMENT TRAIN $50-100mil (Large Pharma) ABS-201 FOR ANDROGENETI C ALOPECI A CAPITAL Category re-defining opportunity for AGA in Ph1/2a trials ABS-201 FOR 2 24 Months (Absci) 6-week Lab in the ENDOMETRI OSI S loop cycle
Slide 4: Absci is the first validated platform to de novo design full length antibodies
FROM CODE TO CLINIC RAISING THE BAR ON DE NOVO DESIGN Absci is the first validated platform to de novo design full length antibodies against ‘zero-prior’ epitopes with atomic accuracy SCAN QR CODE TO DOWNLOAD THE MANUSCRIPT COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 4
Slide 5: Unmet Medical Need / Patient Value
FROM CODE TO CLINIC Strategy to leverage STEP FUNCTION LEAP our de novo design IN PATIENT BENEFIT platform on category creation opportunities UNMET MEDICAL NEED / PATIENT VALUE that: o Addresses large unmet medical need with significant commercial opportunity FITS o Provides step-function EM ENTA L
Slide 6: ABS-201 has the potential to unlock a wholly new category of therapy in hair re-growth
ABS-201 ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” 1. Significant clinical and commercial unmet need in androgenetic alopecia 2. Strong scientific rationale, with validated target, de-risked Mode of Action, and pharmacology 3. Straightforward development
Slide 7: PRLR inhibition for androgenetic alopecia is an innovative alternative to current treatment options
ABS-201 | AGA PRLR inhibition for androgenetic alopecia is an innovative alternative to current treatment options ABS-201 HAS THE PROPOSED DIRECT IMPACT OF ABS-201 ON HAIR CYCLE STAGES POTENTIAL TO: Catagen o Shift the balance in hair cycle stage ↑↑ Apoptosis & Catagen towards anagen phase1,2 with:
Slide 8: Primate model hair regrowth data
ABS 201 | AGA Top head view of Stumptailed Macaque’s showing Terminal hair count ”Thick phenotypic change over time Hairs” in prior bald areas ASSESSMENT AREA = R1 TREATMENT POST-TREATMENT 30 0 BASELI NE 12 WEEKS 28 WEEKS 6 MONTHS 2 YEARS 4 YEARS 25 0 # Thick Hairs 20 MALE 0 150 100 50 FEMALE 0 4 8
Slide 9: ABS-201 in human ex vivo culture study supports MOA in human scalp follicles
ABS-201 | AGA ABS-201 in human ex vivo culture study supports MOA in human scalp follicles Frontotemporal ABS-201 significantly prolongs anagen/inhibits catagen and Hairline Region stimulates hair matrix proliferation Scalp Punch Microscopic hair cycle staging 100 80 % of HFs in each hair 60 cycle s
Slide 10: Additional ABS-201 ex vivo study found
ABS-201 | AGA Additional ABS-201 ex Stem Cell Protection & Maintenance vivo study found: (↑K15+ Stem Cells) o Prolonging anagen phase and blocking catagen, thereby inhibiting telogen effluvium ↑ FGF7 and IGF1 Expression o Protecting and promoting hair follicle stem cells and and restoring CD34+ prog
Slide 11: Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in AGA
ABS-201 | AGA Phase 1/2a trial designed to Single Ascending Dose provide readouts on safety, Cohort 1 Cohort 2 Cohort 3 Cohort 4 tolerability, and PoC in AGA 150mg IV 450mg IV 900mg IV 1800mg IV n=8 n=8 n=8 n=8 o First cohort fully enrolled and dosed - Enrollment of remaining Design Elements: cohort
Slide 12: ABS-201 TPP aims to offer a new treatment category in AGA
ABS-201 | AGA ABS-201 TPP aims to offer a new treatment category in AGA based on efficacy and convenience 80 70 Transplant + oral/topical Efficacy (terminal hairs/cm2) 60 Potential 50 ABS-201 TPP 40 30 PRP Finasteride Oral Minoxidil 20 10 Topical Minoxidil 0 Worse Convenience and Comfort Better * Ba
Slide 13: Consumer Research Validates Market Potential of ABS-201
ABS-201 | AGA Consumer Research 610 Participants: Validates Market Potential 306 Men | 304 Women *ALL PARTICIPANTS EXPERIENCING HAIR LOSS of ABS-201 UP TO UP TO 97% 88% Significant Unmet Need: EXTREMELY OR VERY Driven by psycho-social impacts (loss of confidence, self- LIKELY TO ASK HCP esteem) from
Slide 14: Hair Regrowth Therapy: 80M Patient Funnel
HAIR REGROWTH THERAPY Total AGA pts in the US 50M male, 30M female 80M Patient Funnel Income ≥$75K (US Census) Pts 17-69 yo ~39M >$25B ESTIMATED U.S. TAM Concerned / motivated about hair loss ~26M Strong interest in TPP ~22 – 24M >$40B POTENTIAL GLOBAL TAM Strongest interest in TPP with premium pric
Slide 15: Development of ABS-201 in Endometriosis
ABS 201 | ENDOMETRIOSIS Development of ABS-201 in Endometriosis 1. Addresses Long-standing Unmet Medical Need and Poor standard of care Strong Biological And Clinical 2. Rationale: Including POC for PRLR mechanism in humans 3. Large, untapped market offers significant upside potential COPYRIGHT© 202
Slide 16: PRLR antagonism is a novel and differentiated MoA in Endometriosis
ABS-201 | ENDOMETRIOSIS PRLR antagonism is a novel and differentiated MoA in Endometriosis o Endometriotic lesions produce prolactin under estrogen/progesterone control. PRL and PRLR play a dual role in endometrial lesion development o Excess prolactin promotes lesion growth and pain response and se
Slide 17: PRLR antagonism reduces lesion formation and pain in endometriosis mouse model
ABS-201 | ENDOMETRIOSIS PRLR antagonism reduces lesion formation and pain in endometriosis mouse model Prolactin inhibition decreases endometrial lesion formation in % Distance travelled at Week 7 female mouse interna (compared to baseline) 5 * * * Disease Score 4 3 2 lgG1 – w/o transplant 1 * 0 lgG
Slide 18: ABS-201 in Endometriosis offers a differentiated profile with potential for blockbuster peak sales
ABS-201 | ENDOMETRIOSIS ABS-201 in Endometriosis offers a differentiated profile with potential for blockbuster peak sales NOVEL TR EATMENT OPTI ON FOR ~ 9 M PATIENTS I N THE U . S . AL ONE WI TH ENDOMETR I OS I S o Novel Mechanism: Non–sex- o Best-in-class Potential: steroid (peptide) hormone Super
Slide 19: Advancing and expanding our pipeline of novel & differentiated assets designed using AI
PIPELINE Advancing and expanding our pipeline of novel & differentiated assets designed using AI Lead DC IND* THERAPEUTIC TARGET ID LEAD ID CANDIDATE ID IND-ENABLING PHASE 1 PHASE 2 AREA ABS- 201 Androgenetic Alopecia (PRLR) Ph1 / 2a CLINICAL STAGE Endometriosis (PRLR) Ph1 PIPELINE ABS- 101 INFL. Bo
Slide 20: Multilingual team with expertise in AI and drug creation
TEAM ”Multilingual” LEADERSHIP TEAM: team with expertise in AI and drug Sean McClain Andreas Busch, Zach Jonasson, Amir Shelby Walker, JD Karin Wierinck Christine Lemke Founder, CEO & Board PHD PHD Shanehsazzadeh Chief Legal Officer Chief People Officer SVP, Portfolio & Growth Director Chief Innovat
Slide 21: Absci at a Glance
OVERVIEW Absci at a Glance 140 EMPLOYEES 77,000 SQUARE FEET o State-of-the-art wet and dry lab in Vancouver WA o Absci AI Research (AAIR) lab in NYC 10+ PARTNERS, INCLUDING o Innovation Centre in Zug Switzerland “Multi-lingual” AI + Drug Discovery expertise AI team drawing on experience 3 from tech
Slide 22: Leading AI x Bio platform driving Phase readouts in the next 24 months
CATALYSTS Leading AI x Bio platform driving 2 Phase 2 readouts in the next 24 months ABS-201 in AGA ABS-201 in ENDO o Accelerated Ph1/2a Study o Accelerated Ph1/2a Study initiated Dec 2025 initiated Dec 2025 o Safety, Tolerability, and PK o Phase 2 initiation expected in readout expected 1H 2026 2H2

Absci — 2026 J.P. Morgan Healthcare Conference on 6ix

Absci — 2026 J.P. Morgan Healthcare Conference

Slide 1: Generative AI Drug Creation

Slide 2: Disclaimers

Slide 3: From Code to Clinic: Industrializing Drug Discovery

Slide 4: Absci is the first validated platform to de novo design full length antibodies

Slide 5: Unmet Medical Need / Patient Value

Slide 6: ABS-201 has the potential to unlock a wholly new category of therapy in hair re-growth

Slide 7: PRLR inhibition for androgenetic alopecia is an innovative alternative to current treatment options

Slide 8: Primate model hair regrowth data

Slide 9: ABS-201 in human ex vivo culture study supports MOA in human scalp follicles

Slide 10: Additional ABS-201 ex vivo study found

Slide 11: Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in AGA

Slide 12: ABS-201 TPP aims to offer a new treatment category in AGA

Slide 13: Consumer Research Validates Market Potential of ABS-201

Slide 14: Hair Regrowth Therapy: 80M Patient Funnel

Slide 15: Development of ABS-201 in Endometriosis

Slide 16: PRLR antagonism is a novel and differentiated MoA in Endometriosis

Slide 17: PRLR antagonism reduces lesion formation and pain in endometriosis mouse model

Slide 18: ABS-201 in Endometriosis offers a differentiated profile with potential for blockbuster peak sales

Slide 19: Advancing and expanding our pipeline of novel & differentiated assets designed using AI

Slide 20: Multilingual team with expertise in AI and drug creation

Slide 21: Absci at a Glance

Slide 22: Leading AI x Bio platform driving Phase readouts in the next 24 months

Slide 23: Generative AI Re(Generative) Biology